The PD-1 inhibitors space has become extremely competitive, but the latest data show that there is now an out-right winner in terms of revenue generation.
Both Merck & Co (NYSE: MRK) and Bristol-Myers Squibb (NYSE: BMY) have reported growth in the global revenues of their PD-1 inhibitors, Keytruda (pembrolizumab) and Opdivo (nivolumab), respectively. Merck’s Keytruda is leading in total sales for the global immune checkpoint inhibitor market in third-quarter 2019, indicating that it is rapidly gaining popularity over B-MS’ Opdivo.
While Keytruda’s revenues grew an impressive 62%, compared to third-quarter 2018, to reach $3.1 million, Opdivo sales increased by only 1%, compared to third-quarter 2018, to $1.8 million, says analytics firm GlobalData.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze